06 · M&A, BD & licensing
M&A, BD & licensing
Bookmarks need a Mind Club sign-in. How sign-in works
One licensing deal with disclosed terms, one partnership milestone and one takeover report; no acquisition announced in the window.
| Deal | Asset or platform | Terms, as stated | Area |
|---|---|---|---|
| AbbVie and DISCO Pharmaceuticals | Research collaboration with an option to license AND-gated bispecific antibodies for solid tumors; targets not disclosed | $40M upfront; up to $2.5B in option, development and other milestones; tiered royalties | Oncology |
| Evotec and Bristol Myers Squibb | A second CELMoD protein degrader from their partnership; FDA accepted the IND, Phase 1 expected in 2027 | No financial terms in the reports we read | Oncology |
| Sanofi and Insmed (report) | Bloomberg reports Sanofi is weighing a takeover bid, citing unnamed people | No price reported; no deal announced | Rare & genetic |
BioSpace (11.19) (opens another website in a new tab); PharmExec (11.19) (opens another website in a new tab); GeneOnline (11.20) (opens another website in a new tab); Pharmaceutical Technology (11.20) (opens another website in a new tab) Press. DISCO’s own release, read through Yahoo Finance (11.19) (opens another website in a new tab) Co, is timestamped 11:00 pm PT on 11.18, just before the window; we include it because the 11.19 edition did not cover it. Innogen’s license of efsubaglutide alfa to Arcera came out at 1:56 am PT on 11.19, also before the window, with no amounts disclosed.
RED TEAM
The $2.5B headline assumes every option and milestone is paid on undisclosed targets. The Insmed story rests on unnamed sources, and a deal may never be offered. Analysis